Cited by 39Genetics and Neurodevelopmental DisordersNeuroinflammation and Neurodegeneration MechanismsNeuroscience and Neuropharmacology Research

Persistent astrocyte activation in the fragile X mouse cerebellum

Open access
Pacey, Laura K. K., Guan, Sihui, Tharmalingam, Sujeenthar, Thomsen, Christian, Hampson, David R.·2015·Brain and Behavior

Abstract

Background: Fragile X S yndrome, the most common single gene cause of autism, results from loss of the RNA‐binding protein FMRP. Although FMRP is highly expressed in neurons, it has also recently been identified in glia. It has been postulated that in the absence of FMRP, abnormal function of non‐neuronal cells may contribute to the pathogenesis of the disorder. We previously demonstrated reduced numbers of oligodendrocyte precursor cells and delayed myelination in the cerebellum of fragile X (F mr1) knockout mice. Methods: We used quantitative western blotting and immunocytochemistry to examine the status of astrocytes and microglia in the cerebellum of F mr1 mice during development and in adulthood. Results: We report increased expression of the astrocyte marker GFAP in the cerebellum of F mr1 mice starting in the second postnatal week and persisting in to adulthood. At 2 weeks postnatal, expression of T umor N ecrosis F actor R eceptor 2 (TNFR 2) and L eukemia I nhibitory F actor (LIF) were elevated in the F mr1 KO cerebellum. In adults, expression of TNFR 2 and the glial marker S 100 β were also elevated in F mr1 knockouts, but LIF expression was not different from wild‐type mice. We found no evidence of microglial activation or neuroinflammation at any age examined. Conclusions: These findings demonstrate an atypical pattern of astrogliosis in the absence of microglial activation in F mr1 knockout mouse cerebellum. Enhanced TNFR 2 and LIF expression in young mice suggests that changes in the expression of astrocytic proteins may be an attempt to compensate for delayed myelination in the developing cerebellum of F mr1 mice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/brb3.400

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GFAP, TNFR2, and S100B are increased in the adult Fmr1 KO brain.

    “GFAP, TNFR2, and S100B were increased in the adult Fmr1 KO brain (Pacey et al., 2015).”

    From Astrocytes in fragile X syndrome (2024) · cites this paper as Pacey et al., 2015

    The Results report increased GFAP in the adult Fmr1 KO cerebellar cortex, TNFR2 in its deep white matter, and S100β in its molecular and Purkinje cell layers. The evidence supports the three increases in the cerebellum, but not a broader claim about the adult brain. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Astrocytes in the cerebellum of Fmr1 KO mice display chronic, persistent activation with little or no activation of microglia.

    “Pacey et al. (2015) showed that astrocytes in the cerebellum of Fmr1 KO mice display chronic, persistent activation with little or no activation of microglia.”

    From Astrocytes in fragile X syndrome (2024) · cites this paper as Pacey et al., 2015

  • Expression of glial cell markers TNFR2, LIF, and GFAP are elevated in the Fmr1 KO mouse cerebellum at 2 weeks postnatally.

    “Expression of glial cell markers tumor necrosis factor receptor 2 (TNFR2), leukemia inhibitory factor (LIF), and GFAP were found to be elevated in the Fmr1 KO mouse cerebellum at 2 weeks postnatally.”

    From Astrocytes in fragile X syndrome (2024) · cites this paper as Pacey et al., 2015

  • Astrocytes with abnormally high GFAP have been observed in striatal, hippocampal, cortical, and cerebellar areas of adult Fmr1 KO mice.

    “Astrocytes with abnormally high GFAP, have been observed in striatal, hippocampal, cortical, and cerebellar areas of adult Fmr1 KO mice (Yuskaitis et al., 2010; Pacey et al., 2015).”

    From Astrocytes in fragile X syndrome (2024) · cites this paper as Pacey et al., 2015

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. Adusei, D. C., L. K. Pacey, D. Chen, and D. R. Hampson. 2010 Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 59: 167– 171. 20470805
  2. Ascano, M., Jr., N. Mukherjee, P. Bandaru, J. B. Miller, J. D. Nusbaum, D. L. Corcoran, et al. 2012 FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 492: 382– 386. 23235829 PMC3528815
  3. Ashwood, P., D. V. Nguyen, D. Hessl, R. J. Hagerman, and F. Tassone. 2010 Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis? Brain Behav. Immun. 24: 898– 902. 20102735 PMC3626458
  4. Ashwood, P., P. Krakowiak, I. Hertz‐Picciotto, R. Hansen, I. Pessah, and J. Van de Water. 2011 Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav. Immun. 25: 40– 45. 20705131 PMC2991432
  5. Bagni, C., and B. A. Oostra. 2013 Fragile X syndrome: from protein function to therapy. Am. J. Med. Genet. A 161A: 2809– 2821. 24115651
  6. Bal‐Price, A., and G. C. Brown. 2001 Inflammatory neurodegeneration mediated by nitric oxide from activated glia‐inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 21: 6480– 6491. 11517237 PMC6763071
  7. Callan, M. A., N. Clements, N. Ahrendt, and D. C. Zarnescu. 2012 Fragile X protein is required for inhibition of insulin signaling and regulates glial‐dependent neuroblast reactivation in the developing brain. Brain Res. 1462: 151– 161. 22513101
  8. Cao, Z., S. Hulsizer, Y. Cui, D. L. Pretto, K. H. Kim, P. J. Hagerman, et al. 2013 Enhanced asynchronous Ca(2+) oscillations associated with impaired glutamate transport in cortical astrocytes expressing Fmr1 gene premutation expansion. J. Biol. Chem. 288: 13831– 13841. 23553633 PMC3650419
  9. Carbone, D. L., J. A. Moreno, and R. B. Tjalkens. 2008 Nuclear factor kappa‐B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low‐level inflammatory stimulation with MPTP. Brain Res. 1217: 1– 9. 18508038 PMC2547142
  10. Catania, M. V., R. Giuffrida, G. Seminara, G. Barbagallo, E. Aronica, J. A. Gorter, et al. 2003 Upregulation of neuronal nitric oxide synthase in in vitro stellate astrocytes and in vivo reactive astrocytes after electrically induced status epilepticus. Neurochem. Res. 28: 607– 615. 12675151
  11. Edmonson, C., M. N. Ziats, and O. M. Rennert. 2014 Altered glial marker expression in autistic post‐mortem prefrontal cortex and cerebellum. Mol. Autism 5: 3. 24410870 PMC3914711
  12. Fischer, R., O. Maier, M. Siegemund, H. Wajant, P. Scheurich, and K. Pfizenmaier. 2011 A TNF receptor 2 selective agonist rescues human neurons from oxidative stress‐induced cell death. PLoS One 6: e27621. 22110694 PMC3215731
  13. Fischer, R., H. Wajant, R. Kontermann, K. Pfizenmaier, and O. Maier. 2014 Astrocyte‐specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia 62: 272– 283. 24310780
  14. Forbes‐Lorman, R. M., J. R. Kurian, and A. P. Auger. 2014 MeCP2 regulates GFAP expression within the developing brain. Brain Res. 1543: 151– 158. 24269336
  15. Gholizadeh, S., S. K. Halder, and D. R. Hampson. 2015 Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain. Brain Res. 1596: 22– 30. 25446451
  16. Giampetruzzi, A., J. H. Carson, and E. Barbarese. 2013 FMRP and myelin protein expression in oligodendrocytes. Mol. Cell Neurosci. 56: 333– 341. 23891804 PMC3804070
  17. Goines, P., and J. Van de Water. 2010 The immune system's role in the biology of autism. Curr. Opin. Neurol. 23: 111– 117. 20160651 PMC2898160
  18. Gross, C., M. Nakamoto, X. Yao, C. B. Chan, S. Y. Yim, K. Ye, et al. 2010 Excess phosphoinositide 3‐kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 30: 10624– 10638. 20702695 PMC2924772
  19. Hagerman, R., G. Hoem, and P. Hagerman. 2010 Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol. Autism 1: 12. 20858229 PMC2954865
  20. Hampson, D. R., S. Gholizadeh, and L. K. Pacey. 2012 Pathways to drug development for autism spectrum disorders. Clin. Pharmacol. Ther. 91: 189– 200. 22205199
  21. Higashimori, H., L. Morel, J. Huth, L. Lindemann, C. Dulla, A. Taylor, et al. 2013 Astroglial FMRP‐dependent translational down‐regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse. Hum. Mol. Genet. 22: 2041– 2054. 23396537 PMC3633372
  22. Ishibashi, T., K. A. Dakin, B. Stevens, P. R. Lee, S. V. Kozlov, C. L. Stewart, et al. 2006 Astrocytes promote myelination in response to electrical impulses. Neuron 49: 823– 832. 16543131 PMC1474838
  23. Jacobs, S., and L. C. Doering. 2010 Astrocytes prevent abnormal neuronal development in the fragile x mouse. J. Neurosci. 30: 4508– 4514. 20335488 PMC6634485
  24. Jacobs, S., M. Nathwani, and L. C. Doering. 2010 Fragile X astrocytes induce developmental delays in dendrite maturation and synaptic protein expression. BMC Neurosci. 11: 132. 20955577 PMC2970604
  25. Lee, Y. B., S. Du, H. Rhim, E. B. Lee, G. J. Markelonis, and T. H. Oh. 2000 Rapid increase in immunoreactivity to GFAP in astrocytes in vitro induced by acidic pH is mediated by calcium influx and calpain I. Brain Res. 864: 220– 229. 10802029
  26. Li, X., A. Chauhan, A. M. Sheikh, S. Patil, V. Chauhan, X. M. Li, et al. 2009 Elevated immune response in the brain of autistic patients. J. Neuroimmunol. 207: 111– 116. 19157572 PMC2770268
  27. Liedtke, W., W. Edelmann, P. L. Bieri, F. C. Chiu, N. J. Cowan, R. Kucherlapati, et al. 1996 GFAP is necessary for the integrity of CNS white matter architecture and long‐term maintenance of myelination. Neuron 17: 607– 615. 8893019
  28. Luth, H. J., M. Holzer, U. Gartner, M. Staufenbiel, and T. Arendt. 2001 Expression of endothelial and inducible NOS‐isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res. 913: 57– 67. 11532247
  29. Molofsky, A. V., R. Krencik, E. M. Ullian, H. H. Tsai, B. Deneen, W. D. Richardson, et al. 2012 Astrocytes and disease: a neurodevelopmental perspective. Genes Dev. 26: 891– 907. 22549954 PMC3347787
  30. Naude, P. J., J. A. den Boer, P. G. Luiten, and U. L. Eisel. 2011 Tumor necrosis factor receptor cross‐talk. FEBS J. 278: 888– 898. 21232019
  31. Noble, L. J., F. Donovan, T. Igarashi, S. Goussev, and Z. Werb. 2002 Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J. Neurosci. 22: 7526– 7535. 12196576 PMC2792199
  32. Onore, C., J. Van de Water, and P. Ashwood. 2012 Decreased levels of EGF in plasma of children with autism spectrum disorder. Autism Res. Treat. 2012: 205362. 22937258 PMC3420731
  33. Pacey, L. K., and L. C. Doering. 2007 Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome. Glia 55: 1601– 1609. 17823967
  34. Pacey, L. K., I. C. Xuan, S. Guan, D. Sussman, R. M. Henkelman, Y. Chen, et al. 2013 Delayed myelination in a mouse model of fragile X syndrome. Hum. Mol. Genet. 22: 3920– 3930. 23740941
  35. Pekny, M., and M. Pekna. 2014 Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol. Rev. 94: 1077– 1098. 25287860
  36. Pekny, M., U. Wilhelmsson, and M. Pekna. 2014 The dual role of astrocyte activation and reactive gliosis. Neurosci. Lett. 565: 30– 38. 24406153
  37. Sethna, F., C. Moon, and H. Wang. 2014 From FMRP function to potential therapies for fragile X syndrome. Neurochem. Res. 39: 1016– 1031. 24346713 PMC4024105
  38. Siman, R., J. P. Card, R. B. Nelson, and L. G. Davis. 1989 Expression of beta‐amyloid precursor protein in reactive astrocytes following neuronal damage. Neuron 3: 275– 285. 2518369
  39. Tessier, C. R., and K. Broadie. 2011 The fragile X mental retardation protein developmentally regulates the strength and fidelity of calcium signaling in Drosophila mushroom body neurons. Neurobiol. Dis. 41: 147– 159. 20843478 PMC2982942
  40. Wang, J., and R. S. Al‐Lamki. 2013 Tumor necrosis factor receptor 2: its contribution to acute cellular rejection and clear cell renal carcinoma. Biomed Res. Int. 2013: 821310. 24350291 PMC3848079
  41. Wang, H., L. Ku, D. J. Osterhout, W. Li, A. Ahmadian, Z. Liang, et al. 2004 Developmentally‐programmed FMRP expression in oligodendrocytes: a potential role of FMRP in regulating translation in oligodendroglia progenitors. Hum. Mol. Genet. 13: 79– 89. 14613971
  42. Yang, Q., B. Feng, K. Zhang, Y. Y. Guo, S. B. Liu, Y. M. Wu, et al. 2012 Excessive astrocyte‐derived neurotrophin‐3 contributes to the abnormal neuronal dendritic development in a mouse model of fragile X syndrome. PLoS Genet. 8: e1003172. 23300470 PMC3531466
  43. Yuskaitis, C. J., E. Beurel, and R. S. Jope. 2010 Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. Biochim. Biophys. Acta 1802: 1006– 1012. 20600866 PMC2942952

Cited by

Sorted by citations

Authors
Pacey, L. K. K., Guan, S., Tharmalingam, S., Thomsen, C., & Hampson, D. R.
Affiliations
  • University of Toronto (CA)
  • Lundbeck (United States) (US)
Corresponding author
Hampson, David R.
Venue
Brain and Behavior
Publisher
Wiley
Published
2015-09-25
Volume
5
Issue
10
Pages
e00400-e00400
ISSN
  • 2157-9032 (ISSN-L)
  • 2162-3279
OpenAlex
W2155370827
Cited by
39
References
7
Citations by year
2026: 2 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 4
FWCI
2.75
Type
journal article
Language
en
Open access
Locations
  • Brain and Behavior (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
fragile X syndrome, FMRP, astrocyte activation, cerebellum, glial fibrillary acidic protein, TNFR2, leukemia inhibitory factor, S100β, microglial activation, neuroinflammation, oligodendrocyte precursor cells, delayed myelination, Fmr1 knockout mice, autism spectrum disorder
MeSH terms
Animals, Astrocytes, Autistic Disorder, Cerebellum, Disease Models, Animal, Female, Fragile X Syndrome, Neuroglia, Neurons, Microglia, Mice, Knockout, Mice, Fragile X Mental Retardation Protein, Fragile X Messenger Ribonucleoprotein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review